Donanemab
Down Syndrome
Michael Rafii, MD, PhDmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
33 Active assets in the Down Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vincristine Sulfate National Cancer Institute (NCI) | Phase 3 | BB |
Mercaptopurine Anhydrous National Cancer Institute (NCI) | Phase 3 | BB |
Pegaspargase National Cancer Institute (NCI) | Phase 3 | BB |
Cytarabine Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
Methotrexate National Cancer Institute (NCI) | Phase 3 | BB |
View all 35 →
Same molecule, other indications
Donanemab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →